MMCAP International Inc. SPC, along with its investment manager MM Asset Management Inc., filed a Schedule 13G/A on May 15, 2026, reporting a significant increase in their position in Algoma Steel Group Inc. (ASTL). As of the event date of March 31, 2026, the reporting persons collectively beneficially own 12,845,622 c...

On May 15, 2026, Wellington Management Group LLP filed a Schedule 13G/A reporting an increased stake in Alignment Healthcare, Inc. (ALHC). As of the event date on March 31, 2026, the firm and its affiliated entities, including Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, collectively b...

General Atlantic, L.P. and its affiliated entities filed a Schedule 13G/A on May 15, 2026, disclosing a combined beneficial ownership of 308,852 shares of Class A common stock in Alignment Healthcare, Inc. (ALHC). This represents approximately 0.1% of the company's outstanding shares as of March 31, 2026. The filing in...

Woodline Partners LP has filed a Schedule 13G/A for Aligos Therapeutics, Inc. (ALGS), reporting a beneficial ownership of 239,362 shares of Voting Common Stock. This position represents approximately 4.4% of the company's outstanding shares, based on 5,387,807 shares reported as of March 2, 2026. The reported total inc...

On May 15, 2026, T. Rowe Price Associates, Inc. filed a Schedule 13G/A (Amendment No. 2) regarding its holdings in Alkermes PLC (ALKS). The filing indicates that as of March 31, 2026, the investment adviser beneficially owns 4,664,563 shares of common stock, representing a 2.8% ownership stake in the company. This refl...

Lynx1 Capital Management LP and Mr. Weston Nichols have filed a Schedule 13G/A with the SEC, indicating that they no longer hold a reportable stake in Allogene Therapeutics, Inc. (ALLO). As of the event date of December 31, 2025, the reporting persons disclosed beneficial ownership of 0 shares of Common Stock, represen...

On May 15, 2026, Citadel Advisors LLC and associated reporting persons, including Kenneth Griffin, filed an amended Schedule 13G (Amendment No. 1) regarding their holdings in Allogene Therapeutics, Inc. (ALLO). Citadel Advisors LLC reported beneficial ownership of 5,795,242 shares of common stock, representing a 2.4% s...

On May 15, 2026, Tang Capital Management, LLC, along with Kevin Tang and several affiliated entities (Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc.), filed a Schedule 13G/A regarding their holdings in Altimmune, Inc. (ALT). The fi...

On May 15, 2026, Vestal Point Capital, LP filed a Schedule 13G/A with the SEC, reporting a 6.5% ownership stake in Alto Neuroscience, Inc. (ANRO). The filing indicates that the reporting persons, which include Vestal Point Capital, LP and its Managing Partner, Ryan Wilder, beneficially own 2,064,075 shares of Common St...

On May 15, 2026, Point72 Asset Management, L.P. filed a Schedule 13G/A regarding its holdings in Alto Neuroscience, Inc. (ANRO). The filing indicates that as of March 31, 2026, Point72 Asset Management beneficially owns 503,087 shares of Common Stock, representing approximately 1.6% of the class. This reflects an incre...

Commodore Capital LP, together with its master fund and managing partners Michael Kramarz and Robert Egen Atkinson, has filed a Schedule 13G/A for Alto Neuroscience, Inc. (ANRO). As of March 31, 2026, the filers reported beneficial ownership of 3,588,180 shares of Common Stock, representing a 9.9% ownership stake in th...

Wellington Management Group LLP, along with its affiliated entities Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Ameresco, Inc. (AMRC). The filing reports a combined beneficial owner...

Perceptive Advisors LLC, along with Joseph Edelman and the Perceptive Life Sciences Master Fund, Ltd., filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Amylyx Pharmaceuticals, Inc. (AMLX). The filing indicates that the reporting persons collectively own 8,284,882 shares of common stock, representing ...

Driehaus Capital Management LLC has filed a Schedule 13G/A with the SEC, reporting a new beneficial ownership position in Andersen Group Inc. (ANDG). As of the event date on March 31, 2026, the investment adviser holds 560,207 shares of Class A Common Stock, representing 4.43% of the company's outstanding shares. This ...

On May 15, 2026, Brown Advisory Inc. filed a Schedule 13G/A disclosing a significant position in Andersen Group Inc. (ANDG). As of March 31, 2026, the firm beneficially owns 2,516,555 shares of Class A common stock, representing a 19.89% ownership stake. This filing marks a substantial increase from a previously report...

On May 15, 2026, Biotechnology Value Fund, L.P. (BVF) and its affiliated reporting persons, including Mark N. Lampert, filed a Schedule 13G/A regarding their holdings in Annexon, Inc. (ANNX). As of March 31, 2026, the reporting group collectively beneficially owns 8,698,173 shares of Common Stock, representing approxim...

Nantahala Capital Management, LLC, alongside Wilmot B. Harkey and Daniel Mack, filed a Schedule 13G/A on May 15, 2026, reporting a 6.28% stake in Anteris Technologies Global Corp. (AVR). As of the event date on March 31, 2026, the reporting persons collectively held 6,143,154 shares of common stock. This position inclu...

Nomura Holdings, Inc. and its subsidiary, Nomura Global Financial Products, Inc., filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Anywhere Real Estate Inc. (HOUS). The filing indicates that as of the event date on March 31, 2026, the reporting persons no longer beneficially own any shares of the iss...

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, reporting a 3.55% ownership stake in Apellis Pharmaceuticals, Inc. (APLS). As of the event date of March 31, 2026, the reporting persons beneficially owned 4,532,374 shares of Common St...

RTW Investments, LP and Dr. Roderick Wong have filed a Schedule 13G/A for Apellis Pharmaceuticals, Inc. (APLS), reporting a beneficial ownership of 3,685,045 shares of common stock. This position represents a 2.9% ownership stake based on 127,829,909 shares outstanding as of February 2026. The filing indicates an incre...

On May 15, 2026, Meteora Capital, LLC filed a Schedule 13G/A with the SEC, reporting a decrease in its stake in Apex Treasury Corp (APXT). As of the event date on March 31, 2026, the investment manager and its Managing Member, Vik Mittal, reported beneficial ownership of 2,689,443 shares of Class A common stock. This r...

Two Seas Capital LP, along with Two Seas Capital GP LLC and Sina Toussi, filed a Schedule 13G/A on May 15, 2026, disclosing a significant ownership position in Arbutus Biopharma Corporation (ABUS). As of the event date on March 31, 2026, the reporting persons collectively beneficially own 18,557,543 common shares, repr...

This Schedule 13G/A filing, dated May 15, 2026, indicates that Vestal Point Capital, LP and Ryan Wilder have completely exited their position in Arcellx, Inc. (ACLX). As of the event date of March 31, 2026, the reporting persons report beneficial ownership of 0 shares, representing 0% of the company's outstanding commo...

Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Archer-Daniels-Midland Company (ADM). The filing reports a beneficial ownership of 17,284,627 shares of common sto...

On May 15, 2026, MMCAP International Inc. SPC and its investment manager, MM Asset Management Inc., filed a Schedule 13G/A (Amendment No. 6) regarding their holdings in Aris Mining Corporation (ARMN). The filing indicates that as of March 31, 2026, the reporting persons beneficially own 7,815,142 common shares, represe...